Revvity Announces Financial Results for the Second Quarter of 2026
Revenue of $730 million; pro forma revenue of $711 million; 4% pro forma revenue growth; 3% pro forma organic revenue growth
GAAP EPS from continuing operations of $0.48; adjusted EPS from continuing operations of $1.41; GAAP pro forma EPS from continuing operations of $0.52; pro forma adjusted EPS from continuing operations of $1.41
Enters into definitive agreement to divest China Immunodiagnostics business
Raises full year guidance
